Priliximab

N/A

Report date: 2022/07/20 10:06:34

Base Information

Drug NamePriliximab
Drug Alias NameAnti-CD4 MAbCentaraMT-412cMT-412CEN-000029
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionT-cell surface antigen CD4 inhibitorsImmunosuppressants
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCentocor
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Center For Research Resources
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksWikipedia